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Abstract
Background: Pregnant women are routinely prescribed medicines while self-medicating with herbal natural products
to treat predominantly pregnancy related conditions. The aim of this study was to assess the potential for herb-drug
interactions (HDIs) in pregnant women and to explore possible herb-drug interactions and their potential
clinical significance.
Methods: A cross-sectional survey of women during early pregnancy or immediately postpartum in North-
East Scotland. Outcome measures included; Prescription medicines use excluding vitamins and potential HDIs assessed
using Natural Medicines Comprehensive Database.
Results: The survey was completed by 889 respondents (73% response rate). 45.3% (403) reported the use of at least one
prescription medicine, excluding vitamins. Of those taking prescription medicines, 44.9% (181) also reported concurrent
use of at least one HNP (Range 1–12). A total of 91 different prescription medicines were reported by respondents using
HNPs. Of those taking prescription medicines, 44.9% (181) also reported concurrent use of at least one HNP (Range 1–12).
Thirty-four herb-drug interactions were identified in 23 (12.7%) women with the potential to increase the risk of postpartum
haemorrhage, alter maternal haemodynamics, and enhance maternal/fetal CNS depression.
Almost all were rated as moderate (93.9%), one as a potentially major (ginger and nifedipine) and only one minor
(ondansetron and chamomile).
Conclusion: Almost half of pregnant women in this study were prescribed medicines excluding vitamins and
minerals and almost half of these used HNPs. Potential moderate to severe HDIs were identified in an eighth of
the study cohort. Healthcare professionals should be aware that the concurrent use of HNPs and prescription
medicines during pregnancy is common and carries potential risks.
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Background
Complementary and alternative medicine (CAM) use is
reportedly increasing worldwide, with data from the
United Kingdom (UK), Europe and United States (USA)
confirming that herbal and natural products (HNP) are
the most frequently used form of CAM therapy [1–5].
Although HNP have been used widely for thousands of
years there is a lack of robust data to support their medical
use. Despite the lack of safety and efficacy data the public
do not appear to be deterred from using them with 5.9%–
48.3% of Europeans and 12–18% of North Americans
reportedly using HNP [4, 5]. Herbal medicines are often
promoted as harmless and users typically cite that HNPs
provide a safe alternatives to pharmaceutical medicines, as
a reason for use [6]. However the use of HNP has been as-
sociated with adverse effects due to direct chemical toxicity,
herb-drug and herb-herb interactions, incorrect dosing,
toxic constituents (renal or hepatic toxins), and product
adulteration or contamination with toxic metals, microbes,
or pollutants [7–18].
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Women are recognised to be the major users of
HNP for treatment of disease and maintenance of health
[3–5, 19, 20], and this widespread use also extends into
pregnancy, where reportedly between 10 and 74% of preg-
nant women in Australia, Europe, UK and the USA use
these products [21–30]. Recent data suggest that ap-
proximately 40% of UK pregnant women use HNP to
treat pregnancy related problems such as nausea and
vomiting or as nutritional supplements to aid fetal de-
velopment [26, 27].
Although the potential risks associated with the use of
prescription medicines during pregnancy are well recog-
nised, data from Australia, Europe and North and South
America, suggest that 12–81% of pregnant women are
prescribed medicines by their healthcare professional who
may be unaware of possible HNP use by their patient
[31–35]. Therefore, during pregnancy many women
may be using both HNP and prescribed medicines result-
ing in a risk of an herb-drug interaction which may be sig-
nificant [36, 37]. The current level of concomitant HNP
and prescription medicine use in the UK is unclear, stud-
ies from North America, Europe, Asia and Africa suggest
that between 2.5%–13% of pregnant women use herbal
and natural products together with prescribed medicines
[38–41]. Currently, there are limited published data from
the UK reporting the levels of HNP use together with pre-
scription medicines during pregnancy and the possible
resultant herb-drug interactions.
The aims of this study were to assess the prevalence
and characteristics of HNP use in pregnant women also
taking prescription medicines and to explore the pos-
sible herb-drug interactions and their potential clinical
significance.
What is known about this subject
 Women are recognised to be the major users of
HNP, for treatment of disease and maintenance of
health, and in high, middle and low income
countries this widespread use also extends into
pregnancy.
 Given that 12–81% of pregnant women use
prescription medicines, a significant number are
likely to also be using HNP with the risk of
potential herb-drug interactions.
What this study adds
 Almost half of all pregnant women in our study
population are prescribed medicines and almost half
of these use HNPs.
 The potential for moderate to severe herb-drug
interactions were identified in an eighth of women.
Methods
Data assessing the use of CAM collected from women
attending for their mid-trimester (18–21 weeks) scan
(n = 332) and women, within the first 24 h following a
live birth, admitted to the postnatal unit (n = 557) at
the Royal Aberdeen Maternity Hospital, North-East
Scotland were combined. Data collection was com-
pleted in 2012 and study methods have been reported
in detail elsewhere [26, 27]; brief study details are
given for completeness. Questionnaires based on the
findings of a systematic review assessing the quality of
relevant study methodologies [6] were given to women
attending the antenatal clinic for their mid trimester
scan or on the postnatal ward following delivery. The
questionnaire was written in English only and tested
for face and content validity by a panel of healthcare
professionals, pregnant and postpartum women. The
final questionnaire contained four sections comprising:
health and medication use during pregnancy (4 items); per-
sonal use of CAM therapies (7 items, extensive checklist of
CAM modalities and products); attitudes toward CAM use
during pregnancy (6 items); and demographics (5 items).
Questions were a mix of closed and Likert statements. As
the questionnaire was anonymous no reminders were is-
sued. To optimise the return rate the questionnaire did not
seek information on the quantity, timing, dose or duration
of herb and food supplements taken. From the combined
study populations all women reporting the use of pre-
scribed medicines and/or herbal or natural products were
identified. To help participants to identify correctly the
products or modalities considered as herbal or natural
products a check list was provided listing 40 herbal and
natural products from the Medicines and Healthcare-
Products Regulatory Agency with space for other products
which the respondent might be using. Prescribed medi-
cines were recorded by asking the respondent “Have you
taken any prescribed medicines during this pregnancy? If
yes, please write the names of all the medicines you have
been prescribed.”
Statistical analysis
Data were coded and entered into an SPSS 22.0 data-
base. Descriptive statistics were used to analyse the data
and provide respondent profile. Chi-square was used to
test the associations between age, education and the use
of herbal or natural products; p < 0.05 was considered
statistically significant.
Herb-drug interaction analysis
The potential for herbal and natural product interaction
with prescribed medicines was assessed using the Natural
Medicines Comprehensive Database [42]. This database re-
ports and grades known interactions as major (do not use
combination; contraindicated; strongly discourage patients
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from using this combination; a serious adverse outcome
could occur), moderate (use cautiously or avoid combin-
ation; warn patients that a significant interaction or adverse
outcome could occur), and minor (be aware that there is a
chance of an interaction; advise patients to watch for warn-
ing signs of a potential interaction) together with a descrip-
tion of the mechanism underlying the interaction.
Ethics statement
This research was approved by National Health Service
North of Scotland Research Ethics Committee and
National Health Service Grampian Research and Develop-
ment Committee on June 27, 2011 (REC 11/AL/0094). As
the Ethics Committee required the survey questionnaires to
be fully anonymous and returned directly by respondents
in post-paid envelopes with no record of identifiable data,
written consent to participate was deemed unnecessary.
Results
A total of 889 respondents completed the questionnaire
on herbal and natural products use (332 antenatal, 557
immediate postnatal, response rates 66% and 80% respect-
ively, study period March–August 2012). Of the 889 re-
spondents, 45.3% (403) reported the use of at least one
prescription medicine, excluding vitamins and minerals.
Of the 403 pregnant women reporting the use of prescrip-
tion medicines, 44.9% (181) also reported the concurrent
use of at least one herbal or natural product (Range 1–
12), equating to 20.4% of the total study population.
The demographics of women reporting concurrent use
of HNP and prescription medicines (“Users”) and those
reporting prescription medicines only (“Non-Users”) are
reported in Table 1. “Users” were significantly older (p <
0.05) and had a higher education status (p < 0.05) than
“non-users”. “Users” in the early pregnancy group reported
the use of 16 different herbal and natural products, of
which ginger was the most commonly cited (35.6%),
followed by chamomile (23.2%), cranberry (20.5%), and
fish oil (12,3%). In the late pregnancy group, a total of
20 herbal and natural products were reported, of which
raspberry was most frequently used (42.5%) followed by
cranberry (26.7%), ginger (23.7%), fish oil (14.8%), and
chamomile (11.8%). The majority of “users” (57.1%) re-
ported the use of one HNP, 20.1% two, 15.8% three and
7.0% four or more HNPs (Range 1–6).
Prescription medicine use by “users”
The use of a single prescription medicine was reported
by over half (54%) of “users”, two medicines by 26%,
three by 10%, four by 5% and five or more by 5% (range
1–12). A total of 91 different prescription medicines
were reported by respondents, the top drug groups in
order of frequency were: antibacterials (18.3%); opiate
analgesics (8.3%); anti-emetics (7.1%); thyroid replacement
(7.1%); non-steroidal anti-inflammatory drugs (NSAIDs)
and aspirin (6.6%); laxatives (6.6%); antacids (5.8%), beta-
2-agonists (5%); non-opiate analgesics (paracetamol) 4.6%,
H2 antagonists (4.1%); and antidepressants (4.1%).
The majority of respondents (56.9%) reported the use
of one HNP with prescribed medicines, 20% reported two,
16% three, 5% four and 2% five or more (range 1–6).
Potential herbal and natural products-prescription medicine
interactions
Eight distinct HNP entities were identified as having the
potential to cause interactions with concurrent prescrip-
tion medicines. These were aloe, chamomile, cranberry,
fish oil, ginger, ginseng, grapefruit, and sage. A total of
34 potential herb-drug interactions were identified in 23
(12.7%) of the “users”. Of the 34 potential interactions,
almost all were rated as moderate (93.9%), one as a po-
tentially major (ginger and nifedipine) and only one
minor (ondansetron and chamomile). Two underlying
mechanisms for the potential interactions were pharma-
codynamic, accounting for 54.5% and pharmacokinetic
via inhibition of cytochrome P450 enzymes or decreased
drug absorption, the remainder.
The prescribed drug classes with the potential for
interaction with HNP were antithrombotic agents (7),
antihypertensive agents (6), antidiabetic agents (5), hyp-
notics and anxiolytics (4), opiate analgesics (4), NSAIDs
(3), hormonal therapies (2, prevention of miscarriage),
proton pump inhibitors (1), insulin (1) and anti-emetics
(1). The HNP and interacting prescription medicines
Table 1 Demographics of women reporting concurrent use of
prescription medicines with herbal and natural products (Users)
and women reporting prescription medicine use only (Non-Users)
(n = 403)
“Users”
(n = 174, n (%))
“Non-Users”
(n = 229, n (%))
p-value
(Chi-square)
Age (years)
15–24 20 (11.5) 35 (15.3)
25–34 101 (58) 149 (65)
≥ 35 53 (30.4) 45 (19.7) <0.05
Education level
University 99 (56.9) 108 (47.2)
College 52 (29.8) 63 (27.5)
Secondary school 23 (13.2) 56 (24.4) <0.05
Not stated 2 (0.8)
Number of prescribed medicines
Median (IQR) 1 (1–2) 1 (1–2)
Range 1–12 1–10
Number of herbal/natural products
Median (IQR) 1 (1–2)
Range 1–6
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together with the potential severity and mechanism of
the interaction are reported in Table 2.
Discussion
Almost half of our study population were taking pre-
scription medicines and just under half of these reported
the concurrent use of at least one herbal or natural product.
We identified potential herb-drug interactions in an eighth
of women who concurrently used both HNP and prescrip-
tion medicines, with one interaction being reported as po-
tentially severe, one as mild and the remainder as moderate
in severity.
Herbal medicines are the most common form of CAM
used worldwide [43] with women reportedly the main
users [20]. Despite the lack of robust safety and efficacy
data for HNPs, recent studies suggest that approximately
40% of pregnant women in the UK report herbal and
natural product use during early and or late pregnancy
[26, 27]. In this study we identified that almost half of
pregnant women were using prescription medicines, which
is in agreement with the findings of previous studies report-
ing that 12–81% of pregnant women use prescription
medicines [31–35].
Although the current level of concomitant HNP and
prescription medicine use in the UK is unclear, studies
from North America, Sweden, Kenya and Iran suggest
that between 2.5%–13% of pregnant women use HNP
together with prescribed medicines [38–42]. The levels
of HNP and prescribed medicines use reported in the
published literature are highly variable and generally lower
than those observed in our study; however, there are signifi-
cant methodological differences in the manner in which
data was collected from these different study populations,
which make direct comparison difficult [44].
In this study we identified 34 potential HNP-drug in-
teractions, predominantly classified as moderate with
one mild and one severe, affecting 12.7% of HNP users.
This would suggest that approximately 1 in 20 of all
pregnant women in the UK, who use HNP, are at risk
from a potential herb-drug interaction. While the potential
for herb-drug interactions has been assessed in patients
with a variety of disease states, only one study has reported
on the prevalence and severity of such interactions in the
pregnant population [38]. Moussally et al. identified that
while only 9% of pregnant Canadian women used HNPs,
69% of these consumed at least one prescribed medicine
[38]. Their study noted potential herb-drug interactions for
more than a third of drug-herb combinations of which
more than 1:4 had the potential to lead to serious adverse
effects. In our study we identified that approximately 45%
of women who reported herbal and natural product use
also used prescription medicines, however we observed
only one potentially serious interaction. The reasons for
the lower prevalence of interactions, especially severe
interactions, in our study population is not clear, however
it is likely due to differences in the herbal and natural
products used by the two study populations.
In our study four herbal and natural products, ginger,
chamomile, grapefruit and fish oil, which are frequently used
for the treatment of pregnancy related issues, accounted for
82% of all potential interactions. Moussally et al., however,
reported that green tea, which did not appear in the top 10
herbs used by our cohort, accounted for 30% of all herb-
drug interactions in a Canadian population [38]. Although
we have identified potential rather than actual interactions,
these interactions may give rise to clinically significant ad-
verse events, especially during labour and birth. Such herb-
drug interactions have been previously reported to give rise
to increased risk of bleeding, alteration of maternal haemo-
dynamics and increased risk of central nervous system de-
pression both maternal and fetal/neonatal [45–47]. Herbal
supplements such as valerian, kava and chamomile when
administered with opiate analgesics, which were the second
largest prescribed drug group in our study cohort, may lead
to increased central nervous system depression. Similarly,
NSAIDs, particularly aspirin, have the potential to interact
with herbal supplements which also possess antiplatelet ac-
tivity, such as ginkgo, garlic, ginger, and ginseng, or with
herbs containing coumarin such as chamomile, fenugreek
and red clover, to enhance the risk of bleeding. We did not
look specifically at the use of over the counter medicines
(OTC), however in this study 11 women were prescribed
paracetamol, a medicine which is commonly bought over
the counter in pharmacies or supermarkets. The true use of
paracetamol in our study population is therefore likely to
have been significantly greater than reported. While many
of the public regard paracetamol as a mild analgesic it does
have the potential to interact with a number of herbs and
food supplements such as Echinacea to increase the risk of
bleeding, hepatotoxicity and nephrotoxicity.
Strengths and limitations
Respondents were provided with detailed checklists for
specific herbal and natural products to ensure correct
reporting of use. We have demonstrated previously that
using such a checklist, rather than an open question
about herbal or natural product use, produces a nine-
fold increase in the number of respondents who report
herbal or food supplement use [44].
A limitation of our study however is the use of self-
reported data and sampling from one centre, which may
possibly limit generalizability, however the demographic
makeup of our respondents is identical to that of the
total pregnant population of England and Wales [48] in-
dicating that our results are likely to be generalisable to
the UK. To ensure an optimal response rate the ques-
tionnaire did not ask about the quantity, timing, dose or
duration of herb and food supplements therefore it is
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possible that women stopped taking their herbal medi-
cines when prescribed an interacting medicine. Further-
more we did not collect data on medicines purchased
over the counter (e.g. paracetamol), which may have led
to an underestimation of the number of potential herb-
drug interactions. Although we used a comprehensive
international information source to identify potential in-
teractions, it is possible that further interactions may
have been identified had other information sources been
used or that further herb-herb or herb-drug interaction
are as yet unrecognised or unreported.
Conclusion
In the UK, HNPs are used by almost half of pregnant
women, although most are unaware that they are using
herbal medicines. While HNPs are often promoted as
harmless and users may believe that HNPs provide a safe
alternatives to pharmaceutical medicines, many HNPs
contain active ingredients, which have the potential to
interact with prescribed medication either directly or via
modification of metabolism. In our study almost half of
pregnant women were using prescribed medicines, ex-
cluding vitamins and minerals, and almost half of these
also used HNPs. Because of the large number of HNPs
available to the public it is not surprising that the toxicology
for many is limited, however despite this we identified
potential herb-drug interactions of moderate severity
in approximately one in eight pregnant women using
HNPs. While we were able to identify potential HDIs
we were unable to determine whether individuals were af-
fected clinically, however as there are approximately 700,000
births in the UK annually and approximately one fifth
of these women use prescription and herbal medicines
concurrently the number affected by HDIs is not insignifi-
cant. Healthcare professionals and those recommending
HNPs should be aware that the concurrent use of HNPs
and prescription medicines during pregnancy is common
and may place the mother and fetus at potential risk.
Abbreviations
CAM: Complementary and Alterative Medicine; CNS: Central Nervous System;
HDI: Herbal Drug Interaction; HNP: Herbal and Natural Product; NSAID: Non-
Steroid Anti-Inflammatory Drug; UK: United Kingdom; USA: United States
Acknowledgements
Not applicable
Declaration of transparency
JSM affirms that the manuscript is an honest, accurate, and transparent
account of the study being reported; that no important aspects of the study
have been omitted; and that any discrepancies from the study as planned
have been explained.
Funding
All funding was from institutional resource. JSM, AS are employed by the
University of Aberdeen. DS is employed by the Robert Gordon University. BP
and CR are employed by NHS Scotland. ARP and MAH are employed by the
Hamad Medical Corporation. Qatar. NI is a postgraduate student at the
University of Aberdeen.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
JSM (Principal Investigator), NI, ARP, AS, BP, CR, MAH, DS were involved with
study design, data collection and analysis, and approving the final manuscript
for submission.
Ethics approval and consent to participate
This research was approved by National Health Service North of Scotland
Research Ethics Committee and National Health Service Grampian Research
and Development Committee on June 27, 2011 (REC 11/ AL/0094). As the
Ethics Committee required the survey questionnaires to be fully anonymous
and returned directly by respondents in post-paid envelopes with no record
of identifiable data, written consent to participate was deemed unnecessary.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1The Division of Applied Health Sciences, The University of Aberdeen,
Aberdeen, UK. 2Pharmacy Department, Women’s Hospital-HMC, Doha, Qatar.
3The Department of Obstetrics and Gynaecology, The University of
Aberdeen, Aberdeen, UK. 4The Department of Obstetrics and Gynaecology,
Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK. 5The
Department of Pharmacy, Aberdeen Royal Infirmary, Aberdeen, UK. 6School
of Pharmacy and Life Sciences. Robert Gordon University, Aberdeen, UK.
Received: 27 February 2017 Accepted: 7 December 2017
References
1. Posadzki P, Watson LK, Alotaibi A, Ernst E. Prevalence of use of complementary
and alternative medicine (CAM) by patients/consumers in the UK: systematic
review of surveys. Clin Med. 2013;13(2):126–31.
2. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine
use among adults and children: United States, 2007. Natl Health Stat Report;
Hyattsville, MD: 2008. Natl Health Stat Report; no 12.
3. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of
complementary health approaches among adults: United States, 2002–2012.
Natl Health Stat Report. 2015;10(79):1.
4. AARP NCCAM. Complementary and alternative medicine: what people aged
50 and older discuss with their health care providers. Consumer Survey
Report. 2011, pp. 1–14
5. Eardley S, Bishop FL, Prescott P, Cardini F, Brinkhaus B, Santos-Rey K, et al.
A systematic literature review of complementary and alternative medicine
prevalence in EU. Forsch Komplementmed. 2012;19(Suppl 2):18–28.
6. Pallivalapila AR, Stewart D, Shetty A, Pande B, McLay JS. Complementary
and alternative medicines use during pregnancy: a systematic review of
pregnant women and healthcare professional views and experiences. Evid
Based Complement Alternat Med. 2013 Sep;30:2013.
7. Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG.
2002;109:227–35.
8. Chuang CH, Doyle P, Wang JD, Chang PJ, Lai JN, Chen PC. Herbal medicines
used during the first trimester and major congenital malformations an
analysis of data from a pregnancy cohort study. Drug Saf. 2006;29:537–48.
9. Elvin-Lewis M. Should we be concerned about herbal remedies. J Ethnopharmacol.
2001;75:141–64.
10. Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of ginkgo (Ginkgo
Biloba) during pregnancy and lactation. Can J Clin Pharmacol. 2006;13:
e277–84.
11. Vickers A, Zollman CABC. Of complementary medicine: herbal medicine.
BMJ. 1999;319:1050–3.
McLay et al. BMC Complementary and Alternative Medicine  (2017) 17:543 Page 6 of 7
12. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med. 1998;399:847.
13. Briggs GG, Roger KF, Sumner JY. Drugs in pregnancy and lactation: a
reference guide to fetal and neonatal risk. Philadelphia (PA): Lippincott
Williams & Wilkins; 2012.
14. Moussally K, Bérard A. Exposure to herbal products during pregnancy risk
preterm birth. Eur J Obstet Gynecol Reprod Biol. 2010;150:107–8.
15. Cuzzolin L, Francini-Pesenti F, Verlato G, Joppi M, Baldelli P, Benoni G. Use of
herbal products among 392 Italian pregnant women: focus on pregnancy
outcome. Pharmacoepidem Dr S. 2010;19:1151–8.
16. Steel A, Adams J, Sibbritt D, Broom A, Frawley J, Gallois C. Relationship
between complementary and alternative medicine use and incidence of
adverse birth outcomes: an examination of a nationally representative
sample of 1835 Australian women. Midwifery. 2014 Dec 31;30(12):1157–65.
17. Facchinetti F, Pedrielli G, Benoni G, Joppi M, Verlato G, Dante G, et al. Herbal
supplements in pregnancy: unexpected results from a multicentre study.
Hum Reprod. 2012;27:3161–7.
18. Boivin J, Schmidt L. Use of complementary and alternative medicines
associated with a 30% lower on going pregnancy/live birth rate during 12
months of fertility treatment. Hum Reprod. 2009;24:1626–31.
19. Graham RE, Ahn AC, Davis RB, O’Connor BB, Eisenberg DM, Phillips RS. Use
of complementary and alternative medical therapies among racial and
ethnic minority adults: results from the 2002 National Health Interview
Survey. J Natl Med Assoc. 2005;97:535–45.
20. Hunt KJ, Coelho HF, Wider B, Perry R, Hung SK, Terry R, et al. Complementary
and alternative medicine use in England: results from a national survey. Int J
Clin Pract. 2010;64(11):1496–502.
21. Kennedy DA, Lupattelli A, Koren G, Nordeng H. Herbal medicine use in
pregnancy: results of a multinational study. BMC Complement Altern Med.
2013;13:355.
22. Holst L, Norderg H, Haavik S. Use of herbal drugs during early pregnancy in
relation to maternal characteristics and pregnancy outcome.
Pharmacoepidem Dr S. 2008;17:151–9.
23. Adams J, Lui CW, Sibbritt D, Broom A, Wardle J, Homer C, et al. Women’s
use of complementary and alternative medicine during pregnancy: a critical
review of the literature. Birth. 2009;36(3):237–45.
24. Fugh-Berman A, Kronenberg F. Complementary and alternative medicine
(CAM) in reproductive–age women: a review of randomized controlled
trials. Reprod Toxicol. 2003;17(2):137–52.
25. Hall HG, McKenna LG, Griffiths DL. Midwives’ support for complementary
and alternative medicine: a literature review. Women Birth. 2012;25(1):4–12.
26. Pallivalapilla AR, Stewart D, Shetty A, Pande B, Singh R, McLay JS.
Complementary and alternative medicine use during early pregnancy. Eur J
Obstet Gynecol Reprod Biol. 2014;181:251–5.
27. Pallivalapilla AR, Stewart D, Shetty A, Pande B, Singh R, McLay JS. Use of
complementary and alternative medicines during the third trimester. Obstet
Gynecol. 2015;125(1):204–11.
28. Forster DA, Denning A, Wills G, Bolger M. McCarthy. Herbal medicine use
during pregnancy in a group of Australian women. BMC Pregnancy
Childbirth. 2006;6:21.
29. Westfall RE. Herbal medicine in pregnancy and childbirth. Adv Ther.
2001;18(1):47–55.
30. Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among
400 Norwegian women. Pharmacoepidem Dr S. 2004;13(6):371–80.
31. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, et
al. Medication use during pregnancy, with particular focus on prescription
drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51–e1.
32. Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME,
et al. Medication use in pregnancy: a cross-sectional, multinational web-
based study. BMJ Open. 2014;4(2):e004365.
33. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug
use during pregnancy in Sweden–assessed by the prescribed drug register
and the medical birth register. Clinical Epidemiol. 2011;3:45–50.
34. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during
pregnancy in developed countries: a systematic review. Pharmacoepidem
Dr S. 2011;20:895–902.
35. Lee E, Maneno MK, Smith L, Weiss SR, Zuckerman IH, Wutoh AK, et al.
National patterns of medication use during pregnancy. Pharmacoepidem Dr
S. 2006; 1; 15(8):537–545.
36. Palmer ME, Haller C, McKinney PE, Klein-Schwartz W, Tschirgi A, Smolinske
SC, et al. Adverse events associated with dietary supplements: an
observational study. Lancet. 2003;361:101–6.
37. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed
drugs: an updated systematic review. Drugs. 2009;69(13):1777–98.
38. Moussally K, Oraichi D, Bérard A. Herbal products use during pregnancy:
prevalence and predictors. Pharmacoepidem Dr S. 2009;18(6):454–61.
39. Mothupi MC. Use of herbal medicine during pregnancy among women
with access to public healthcare in Nairobi, Kenya: a cross-sectional survey.
BMC Complement Altern Med. 2014;14:432.
40. Nordeng H, Bayne K, Havnen GC, Paulsen BS. Use of herbal drugs during
pregnancy among 600 Norwegian women in relation to concurrent use of
conventional drugs and pregnancy outcome. Complement Ther Clin Prac.
2011;17(3):147–51.
41. Tabatabaee M. Use of herbal medicine among pregnant women referring
to Valiasr hospital in Kazeroon, Fars, south of Iran. J med. Plants. 2011;10(37):
96–108.
42. The Natural Medicines Comprehensive Database. http://naturaldatabase.
therapeuticresearch.com/home.asp. Accessed 10/2016.
43. Robinson MM, Zhang X. Traditional medicines: global situation, issues and
challenges. The World Medicines Situation. 2011 (3rd ed). WHO Geneva, 1–14.
44. Pallivalapila AR, Stewart D, Shetty A, Pande B, Al Hail M, McLay JS. Asking
the right question. A comparison of two approaches to gathering data on
'Herbals' use in survey based studies. PLoS One. doi:10.1371/journal.pone.
0150140.
45. Kuczkowski KM. Labor analgesia for the parturient with herbal medicines
use: what does an obstetrician need to know? Arch Gynecol Obstet. 2006;
274(4):233–9.
46. Abebe W. Herbal medication: potential for adverse interactions with
analgesic drugs. J Clin Pharm Ther. 2002;27(6):391–401.
47. Smeriglio A, Tomaino A, Trombetta D. Herbal products in pregnancy:
experimental studies and clinical reports. Phytother Res. 2014;28(8):1107–16.
48. Henderson J, Gao H, Redshaw M. Experiencing maternity care: the care
received and perceptions of women from different ethnic groups. BMC
Pregnancy Childbirth. 2013;13:196.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
McLay et al. BMC Complementary and Alternative Medicine  (2017) 17:543 Page 7 of 7
